Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | Synapse

March 21, 2018Open Access

Ver artículo completo

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. SeymourSouth Australia Pathology

Thomas J. KippsThe Wistar Institute BEBarbara EichhorstTH Köln - University of Applied Sciences

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471 .).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Seymour et al. (Wed,) studied this question.

synapsesocial.com/papers/69936e1f53522ac2836263e8 https://doi.org/https://doi.org/10.1056/nejmoa1713976

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL).2016 · 4 citations
2International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use.1997 · 113 citations
3The National Comprehensive Cancer Network1998 · 16,870 citations
4Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia2011 · 17 citations
5Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome.1996 · 293 citations